Otsuka Pharmaceutical (OTSKY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov26

Otsuka Holdings Co., Ltd. Receives FDA Accelerated Approval to Reduce Proteinuria in IgAN Patients

00:01

Nov25

Otsuka Pharmaceuticals Submits New Drug Application for ADHD to FDA

00:23

Nov9

Otsuka Holdings Announces Positive Interim Results for Phase III Trial of IGA Nephropathy Treatment Drug

23:56

Oct31

Otsuka Pharmaceutical released FY2025 Q3 earnings on October 31 During-Market (EST), actual revenue USD 4.292 B (forecast USD 4.251 B), actual EPS USD 0.7907

20:00

Otsuka Pharmaceutical released FY2025 9 Months Earnings on October 31 During-Market (EST), actual revenue USD 12.31 B, actual EPS USD 1.8991

20:00

Otsuka Pharmaceutical Profits Up 27% in Nine Months

09:28

Schedules & Filings

Schedules

Filings

Oct31

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 4.292 B, Net Income 835.15 M, EPS 0.7907

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 4.131 B, Net Income 611.59 M, EPS 0.5789

Jun30

Distribution Plan(EST)

Cash dividend 0.2036 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change